• metastatic/adv melanoma (mML)
• mML - (neo)adjuvant (NA)
• mML - NA - all population 9
• mML - NA - PDL1 positive 1
• mML - 1st line (L1)
• mML - L1 - all population 7
• mML - L1 - BRAF mutant 2
• mML - L1 - BRAF wild 3
• mML - 2nd line (L2)
• mML - L2 - all population 11
• mML - L2 - BRAF mutant 1
• mesothelioma (MS)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• Ipilimumab (10 mg/kg)
• anti-PD-(L)1
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• Immune checkpoint association
• nivolumab plus ipilimumab

• versus all
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs ipilimumab based treatment
• vs ipilimumab alone
• vs Ipilimumab (10 mg/kg)
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs Immunostimulant
• vs interferon alpha
• vs non active control
• vs placebo

  All patients Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type Gender, female Gender, male PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M1A stage M1B stage M1C stage M1C (with brain metastasis)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mML - (neo)adjuvant (NA), immune chekpoint inhibitors vs. placebo, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;